Briefing.com
Get the live stock market analysis, data, and investment ideas you need to stay fully informed. We provide independent, live market analysis of the U.S.
and international equity markets. It’s our passion, and has been since Dick Green, one of the most-recognized authorities in economic and financial market analysis, founded the Chicago-based company in 1992. We were the first company to use the power of the Internet to provide live market coverage, commentary and analysis. And as the Internet has grown, so have we. Our content now serves mil
06/23/2026
still has exposure to attractive power, utility, and data-center infrastructure themes, but the story has shifted from secular growth to ex*****on risk. Investors need proof that the six troubled Renewables projects are a finite cleanup, not a broader structural issue. See the full analysis: https://www.briefing.com/story-stocks/archive/2026/6/23/primoris-services-power-surge-shorts-out-as-renewables-cost-overruns-trigger-guidance-cut-(prim)?utm_campaign=storystocks&utm_medium=social&utm_source=fb&utm_content=link $PRIM
06/23/2026
Carnival’s demand backdrop remains strong, with record net yields, healthy bookings, and solid onboard spending. The issue is earnings translation: higher fuel costs are limiting upside, making investors question how much of the cruise recovery can flow through to FY26 EPS. See the full analysis: https://www.briefing.com/story-stocks/archive/2026/6/23/carnival-cruises-past-q2-eps-estimates-but-guidance-leaves-investors-unimpressed-(ccl)?utm_campaign=storystocks&utm_medium=social&utm_source=fb&utm_content=link
06/22/2026
Options market implied volatility is signaling elevated expectations for near-term stock movement in this week’s earnings, with standing out against historical norms. Read the latest Special Report: https://briefing.com/todays-free-feature?utm_campaign=freefeature&utm_medium=social&utm_source=fb&utm_content=link
06/22/2026
is trading higher after agreeing to buy Apogee Therapeutics for $135.11/share in cash, valuing $APGE at about $10.9 bln. The deal deepens ABBV’s immunology pipeline, but investors will be watching the price tag, clinical risk, and long path to EPS accretion. See the full analysis: https://www.briefing.com/story-stocks/archive/2026/6/22/abbvie-catches-apogee-fever-109b-deal-expands-immunology-and-asthma-pipeline?utm_campaign=storystocks&utm_medium=social&utm_source=fb&utm_content=link
06/22/2026
's Arcosa deal adds scale in aggregates, infrastructure products, energy transmission, and grid modernization, fitting its North American growth strategy. The debate is whether the company can justify the full valuation through synergies, accretion, deleveraging, and disciplined integration. See the full analysis: https://www.briefing.com/story-stocks/archive/2026/6/22/crh-slips-as-arcosa-deal-raises-questions-around-price-and-ex*****on-(crh)?utm_campaign=storystocks&utm_medium=social&utm_source=fb&utm_content=link
06/22/2026
The market is treating U.S.-Iran diplomacy as a day-by-day relief trade, with lower oil and semiconductor strength supporting sentiment. AI infrastructure remains the bigger leadership story, as ’s power deal with reinforces how far the data-center buildout is reaching. Read the premarket setup in today's Page One: https://www.briefing.com/page-one/archive/2026/6/22/seeing-a-basis-to-be-rationally-exuberant?utm_campaign=pageone&utm_medium=social&utm_source=fb&utm_content=link
06/18/2026
(-6%) is trading lower after a slight Q1 EPS miss and cautious Q2 commentary offset a revenue beat and reaffirmed FY27 guidance. Identical sales ex-fuel rose just 1.0%, while gross margin pressure and a value-focused consumer are keeping investors cautious. See the full analysis: https://www.briefing.com/story-stocks/archive/2026/6/18/kroger-slips-as-q1-sales-beat-fails-to-ease-margin-and-comp-concerns-(kr)?utm_campaign=storystocks&utm_medium=social&utm_source=fb&utm_content=link
06/18/2026
’s move reflects renewed value being placed on its role as a domestic foundry partner, especially if Apple becomes involved. The debate is whether this becomes a meaningful commercial relationship or remains a sentiment-driven validation point until node, volume, and economics are confirmed. See the full analysis: https://www.briefing.com/story-stocks/archive/2026/6/18/intel-jumps-as-trumps-apple-comments-fuel-hopes-for-usbased-chip-manufacturing-tie-up-(intc)?utm_campaign=storystocks&utm_medium=social&utm_source=fb&utm_content=link
06/18/2026
The Fed did not raise rates, but it did change the market’s rate-cut narrative. The Big Picture breaks down why Warsh’s hawkish pause, higher inflation projections, a bear flattener in Treasuries, and a new Fed communication style signal that policy change has already arrived. https://www.briefing.com/the-big-picture/archive/2026/6/17/warsh-signals-new-fed-era?utm_campaign=bigpicture&utm_medium=social&utm_source=fb&utm_content=link
06/18/2026
Fed Chair Warsh made clear that price stability is still the priority, pushing back against hopes for near-term cuts. The market is still rallying anyway, as lower oil, resilient jobless claims, semiconductor strength, and the AI buildout keep risk appetite alive. Read the premarket setup in today's Page One: https://www.briefing.com/page-one/archive/2026/6/18/market-plying-its-buythedip-trade-after-postfomc-selloff?utm_campaign=pageone&utm_medium=social&utm_source=fb&utm_content=link
Click here to claim your Sponsored Listing.
Telephone
Website
Address
Oakbrook Terrace
Oakbrook Terrace, IL
Opening Hours
| Monday | 8am - 5pm |
| Tuesday | 8am - 5pm |
| Wednesday | 8am - 5pm |
| Thursday | 8am - 5pm |
| Friday | 8am - 5pm |